RxDoctor Payments Data

Elizabeth Meinhart

Family · Effingham, ILNPI 1467745208

Payments from drug & device makers

$6,748in general payments, 2019–2025

Across 381 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Sun Pharmaceutical Industries Inc.$422
  • Johnson & Johnson$392
  • Novartis$369
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,14391%
  • Education$6059%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,748 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$128,143
Medicare patients
606
Services billed
6,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa25$501,499
Cosentyx Unoready PenSecukinumab32$392,949
Dupixent PenDupilumab72$266,247
TremfyaGuselkumab14$184,214
Taltz AutoinjectorIxekizumab25$171,548
Cosentyx Sensoready (2 Pens)Secukinumab22$162,567
Humira(Cf) PenAdalimumab18$151,053
OtezlaApremilast30$146,189
ZoryveRoflumilast11$8,940
Fluorouracil73$5,703
Betamethasone Dipropionate103$3,896
Metronidazole58$3,157
Clobetasol Propionate17$1,498
Ketoconazole51$1,364
Triamcinolone Acetonide119$1,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$392$184,21414 claims
AmgenOtezla$1,246$146,18930 claims
Arcutis Biotherapeutics, Inc.Zoryve$152$8,94011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Effingham

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →